Abstract
TALA is a poly (ADP-ribose) polymerase inhibitor (PARPi) approved as monotherapy for germline BRCA1/2-mutated HER2-negative advanced breast cancer. PARPi have demonstrated substantial clinical efficacy in homologous recombination repair (HRR)/DNA damage response (DDR)-altered metastatic castration-resistant prostate cancers (mCRPC). Phase III study results (de Bono et al. N Engl J Med. 2020;382:2091-2102) led to the approval of olaparib for mCRPC. ENZA is an androgen receptor (AR) inhibitor and established therapy for mCSPC.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have